Activities of sitafloxacin (DU-6859a),either singly or in combination with rifampin, against Mycobacterium ulcerans infection in mice

Journal of Chemotherapy

Volumn 15, Issue 1, 2003, Pages 47-52

  Dhople, Arvind M ^a,c   Namba, K ^b  

^a FLORIDA INSTITUTE OF TECHNOLOGY   (United States)

^b DAIICHI SANKYO CO   (Japan)

^c Florida Institute of Technology   (United States)

Author keywords

Mouse footpads; Mycobacterium ulcerans; Ofloxacin; Rifampin; Sitafloxacin

Indexed keywords

OFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; SITAFLOXACIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIAL GROWTH; BACTERICIDAL ACTIVITY; CONTROLLED STUDY; DOSE CALCULATION; DRUG ACTIVITY; DRUG EFFICACY; FEEDING; FOOT PAD; GROWTH INHIBITION; IN VIVO STUDY; MALE; MOUSE; MYCOBACTERIOSIS; MYCOBACTERIUM ULCERANS; NONHUMAN;

EID: 0037300837     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.2003.15.1.47     Document Type: Article

References (20)

1. MacCallum p, Tolhurst JC, Buckle G, Sissons HA. New mycobacterial infection in man: clinical aspects. J Path Bact 1948; 60: 93-102.
2. World Health Organization. World Health Organization targets untreatable ulcer: report from the first international conference on Buruli ulcer control and research, Yamousoukro (Cote d'Ivoire). Inter Press Service, July 31, 1998.
3. Horsburgh CR Jr, Meyers WM. Buruli ulcer. In: Horsburgh CR Jr, Nelson AM, eds. Pathology of emerging infections. Washington DC: American Society for Microbiology Press. 1997: 119-26.
4. World Health Organization. Website: http://www.who.int/gtb-buruli/index.html
5. Weir E. Buruli ulcer: the third most common Mycobacterial infection. Can Med Assoc J 2002; 166:1691.
6. Amofah G, Bonsu F, Tetteh C, et al. Buruli ulcer in Ghana: results of a national case search. Emerging Infect Dis 2002; 8:167-70.
7. Marsollier L, Robert R, Aubry J, et al. Aquatic insects as a vector for Mycobacterium ulcerans. App Environ Microbiol 2002; 68:4623-8.
8. Schroeder KH. Investigation in the relationship of Mycobacterium ulcerans to Mycobacterium buruli. Am Rev Resp Dis 1975; 111: 559-62.
9. Srivastava A, Singh NB, Gupta SK. Prospective treatment for Mycobacterium ulcerans infection in rat and mice through combined therapy with rifampin and septran. Curr Sci 1984; 53: 487-8.
10. Meyers WM, Shelly WM, Connor DH. Heat treatment of Mycobacterium ulcerans infections without surgical incision. Am J Trop Med 1974; 23: 924-9.
11. Bentoucha A, Robert J, Dega H, Lounis N, Jarlier V, Grosset J. Activities of new macrolides and fluoroquinolones against Mycobacterium ulcerans infection in mice. Antimicrob Agents Chemother 2001; 45: 3109-12.
12. Tomioka H, Sato K, Akaki T, Kajitani H, Kawahara S, Sakatani M. Comparatice in vitro antimicrobial activities of the newly synthesized quinolone HSR-903, sitafloxacin (DU-6859a), gatifloxacin (AM-1155) and levofloxacin against Mycobacterium tuberculosis and Mycobacterium avium complex. Antimicrob Agents Chemother 1999; 43:3001-4.
13. Sheppard CC. The experimental disease that follows the injection of human leprosy bacilli into footpads of mice. J Exp Med 1960; 112: 445-54.
14. Dhople AM. In vivo susceptibility of Mycobacterium ulcerans to KRM-1648, a new benzoxazinorifamycin, in comparison with rifampin. Arzneim Forsch/Drug Res 2001; 51: 501-5.
15. Tomioka H, Sato K, Shimizu T, Sano C. Anti-Mycobacterium tuberculosis activities of new fluoroquinolones in combination with other antituberculous drugs. J Infect 2002; 44: 160-5.
16. Tomioka H, Sano C, Sato K, Shimizu T. Antimicrobial activities of clarithromycin, gatifloxacin and sitafloxacin, in combination with various antimycobacterial drugs against extracellular and intramacrophage Mycobacterium avium complex. Inter J Antimicrob Agents 2002; 19:139-45.
17. Horsburgh CR Jr. Epidemiology of disease caused by nontuberculous mycobacteria. Semin Resp Infect 1996; 11: 244-51.
18. World Health Organization. Buruli ulcer disease. Weekly Epidemiological Record 2002; 77: 271-5.
19. Thangaraj HS, Adjei O, Allen BW, Portaels F, Evans MRW, Banerjee D. In vitro activity of ciprofloxacin, sparfloxacin, ofloxacin, amikacin and rifampicin against Ghanaian isolates of Mycobacterium ulcerans. J Antimicrob Chemother 2000; 45: 231-3.
20. Espey D, Djomand G, Diomande I, et al. Pilot study of treatment of Buruli ulcer with rifampin and dapsone. Int J Infect Dis 2002; 6:60-5.